« Return to News | Awards & Advancement

De Silva named president and CEO of Endo Health Solutions

Wednesday, February 27, 2013 11:25 AM

Endo Health Solutions, a Malvern, Penn.-based diversified healthcare company, has named Rajiv De Silva as president and CEO, effective March 18. De Silva, who will also join the Endo board of directors, succeeds David Holveck, who is retiring.

De Silva brings deep experience in the pharmaceutical sector. He most recently served as president of Valeant Pharmaceuticals, a $20 billion market capitalization specialty pharmaceutical company with a presence in the U.S. and a wide range of international markets.  While at Valeant from 2009 to 2013, De Silva also served as chief operating officer of Valeant's specialty pharmaceuticals business. Prior to joining Valeant, he served as a senior executive at Novartis from 2003 to 2008, most recently serving as president of its vaccines business in the U.S. and the head of vaccines in the Americas. De Silva also served as president and CEO of Novartis Pharmaceuticals Canada and global head of strategic planning for Novartis Pharma. Earlier in his career, he was a principal at McKinsey & Company, where he served as a member of the partnership group that led the global Pharmaceutical and Medical Products practice.

De Silva currently serves on the board of AMAG Pharmaceuticals, a publicly traded specialty pharmaceutical company focused on nephrology, hematology, and oncology.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.